Shingai Machingaidze, Suzanne Verver, Humphrey Mulenga, Deborah-Ann Abrahams, Mark Hatherill, Willem Hanekom, Gregory D. Hussey, and Hassan Mahomed Am.

Slides:



Advertisements
Similar presentations
TB Disease and Latent TB Infection
Advertisements

Implementing NICE guidance
TB in Tennessee The Good, the Bad, and the Ugly Jason Cummins, MPH April 30, 2014.
Tuberculosis in Children: Prevention Module 10C - March 2010.
Hepatitis c and tuberculosis Tumelo Roestoff FCP(SA) Fellow of Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital.
Latent TB When infected with M Tuberculosis, but do not have active tuberculosis disease. Patients are not infectious. TB infections in Australia are predominantly.
TB chemoprophylaxis Graham Bothamley Clinical Director, NE London TB Network.
Tuberculosis Control What’s New. TB Regional Nurse Update Teri Lee Dyke, RN, BSN, CIC Julie McCallum, RN, MPH Regional TB Nurse Consultants.
Interferon-gamma Release Assays: the Good, the Bad, and the Ugly Susan E. Dorman, MD Center for TB Research Johns Hopkins University School of Medicine.
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
TB Testing Current Thinking
4/25/2014 Mantoux Skin Testing Joan E. McMahon, RN, MPH Tuberculosis Educator Breathe Pennsylvania.
Update on Interferon Gamma Release Assays for the Laboratory Detection of Mycobacterium tuberculosis Infection David Warshauer, Ph.D., D(ABMM) Deputy Director.
October 3, Serial Testing of Health Care Workers for Tuberculosis Using Interferon-γ Assay Madhukar Pai, et. al. American Journal of Respiratory.
TB or not TB ? Mahmoud Abu-Shakra Rheumatic disease Unit
Culture Conversion and Self- Administered Therapy in Privately Managed Tuberculosis Patients Melissa Ehman MPH, Jennifer Flood MD MPH, Pennan Barry MD.
1 Meeting with Contacts for TB Assessment. Learning Objectives After this session, participants will be able to: 1.Explain why contact assessments are.
Allen Kraut, MD, FRCPC Medical Director, Occupational Health WRHA
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
New Entrant TB Screening Dr. John P. Watson Consultant Respiratory Physician.
IGRAs in Practice: The San Francisco Health Department Experience Jennifer Grinsdale, MPH Program Manager/Epidemiologist Acting Director Tuberculosis Control.
Use of 12 weekly doses of isoniazid and rifapentine for the treatment of latent tuberculosis − Connecticut , Kelley Bemis, MPH CDC/CSTE Applied.
Screening for TB.
بسم الله الرحمن الرحيم. A 25 year old Saudi male applied to work as paramedic. He has no symptoms or history of contact with sick patients. His physical.
IGRAs: Should they replace the TST in the identification of latent tuberculosis? Objectives Describe how interferon-gamma release assays (IGRAs) work.
Recent Epidemiologic Situations of TB in Myanmar -Preliminary Review of Data from routine TB surveillance focusing on Case Finding- 9 May 2014, Nay Pyi.
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
Tuberculosis August 17, 2010 Tuberculosis Mycobacterium tuberculosis – Fastidious, aerobic, acid-fast bacillus Tremendous increase in incidence over.
More information © 2015 Denver Public Health Michelle K Haas, Kaylynn Aiona, Pete Dupree, Ellen Brilliant, Robert Belknap Improving access to Tuberculosis.
Diagnosis of pulmonary tuberculosis
IFN-γ Release Assays in the Diagnosis of Latent Tuberculosis Infection among Immunocompromised Adults Gil Redelman-Sidi and Kent A. Sepkowitz Am J Respir.
Roundtable. Detection and treatment of TB Andrew Black.
Depart. of Pulmonology 백승숙. More than 80% of cases of tuberculosis in the United States –The result of reactivated latent infection –Nearly all these.
Latent Tuberculosis Infection Georges KHAYAT Associate Professor, Faculté de Médecine, Université Saint Joseph.
SAFETY AND EFFICACY OF MVA85A, A NEW TUBERCULOSIS VACCINE, IN INFANTS PREVIOUSLY VACCINATED WITH BCG: A RANDOMISED, PLACEBO-CONTROLLED PHASE 2B TRIAL Michele.
TB: The Elispot In The Room Dr Jessica Potter TB Research Registrar Barts Health NHS Trust.
New WHO algorithm to prevent TB deaths in seriously ill patients with HIV Yohhei Hamada TB/HIV and Community Engagement.
TB Disease and Infection
Ann Rheum Dis 2012;71:1783–1790. doi: /annrheumdis
Institute for Health Service Research for Healthcare Workers (CVcare)
Whole-Genome Sequencing; It’s Not Just For Epis
Infant born with mother Tuberculosis
Copyright © 2009 American Medical Association. All rights reserved.
Government of Swaziland
Indeterminate and inconclusive results are common when using Interferon Gamma Release Assay as screening for TB in patients with IBD Nasr I, Goel RM, Ward.
Test Variability of the QuantiFERON-TB Gold In-Tube Assay in Clinical Practice John Z. Metcalfe, Adithya Cattamanchi1, Charles E. McCulloch, Justin D.
Philippe Glaziou Geneva, 12 October 2009
Volume 135, Issue 4, Pages (April 2009)
Volume 145, Issue 3, Pages (March 2014)
Figure 1. Paradigm for evaluation of those with latent tuberculosis infection (LTBI) based on risk of infection, risk of progression to tuberculosis, and.
QuantiFERON® Blood Test for the Detection of
Volume 142, Issue 1, Pages (July 2012)
Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors 
CDC Guidelines for Use of QuantiFERON®-TB Gold Test
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
بسم الله الرحمن الرحيم.
Mark Lobato, MD Division of TB Elimination
Lei Gao, Qi Jin  The Lancet Infectious Diseases 
Current Concepts in the Management of Tuberculosis
Tuberculosis in prisons TUBS02
Which is true about a tuberculin skin test (TST):
Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors 
Is better than none at all
Tb: Screening & Diagnosis (1)
Cheng shiming National TB Center in China May,3, 2004
Algorithm for TB Testing in Children
Tuberculosis.
Tuberculosis is an infection that is transmitted though airborne particles. It is an uncommon infection in Canada, but is still seen in indigenous populations.
5th edition NTP MANUAL OF PROCEDURES Case Finding
Evidence Based Diagnosis
Presentation transcript:

Shingai Machingaidze, Suzanne Verver, Humphrey Mulenga, Deborah-Ann Abrahams, Mark Hatherill, Willem Hanekom, Gregory D. Hussey, and Hassan Mahomed Am J Respir Crit Care Med Vol 186, pp 1051–1056, Nov 15, 2012 R1 김민제 1 Predictive Value of Recent QuantiFERON Conversion for Tuberculosis Disease in Adolescents

Background  IGRAs (IFN-g release assays)  A new tool for the diagnosis of latent tuberculosis (TB) infection  Detection of INF- g released by T cells (after exposure of mononuclear cells to M. tuberculosis)  Fetures  Unaffected by prior BCG vaccination  Ex vivo assays (Require one visit)  Able to be repeated without sensitization or boosting  Standardized interpretation  IGRAs have been recommended for serial testing for TB infection in populations with continued risk of TB exposures 2

Background  Recent TST (Tuberculin Skin Test) conversion (risk of developing active TB disease)  However, recent IGRA conversion remains unknown  What is an IGRA “Conversion”  What is the “Prognosis” of IGRA conversion  What is an IGRA “Reversion”  Evidence is still required to answer key questions 3

Objective  The incidence rate of active TB disease after recent QuantiFERON Gold In-Tube (QFT) conversion in adolescents compared with those who did not convert  Assess “Predictive value of QTF conversion for active TB disease”  Assess “Effect of varying the definition of QFT conversion on the TB incidence rate” 4

Methods 5  Extension of ACS*  Prospective epidemiological cohort study of TB disease in 12 to 18 yrs of age  Followed for at least 2yrs From “July 2005” untill “February 2009”  QFT tests were scheduled for all participants at baseline and at 2 yr follow-up  “QFT nonconverters” : Remained QFT negative  “QFT converters” : Negative at baseline  Positive at 2yr follow-up visit  Selected participants underwent further period of observation for incident TB disease from March 2009 until September 2010 * ACS : Adolescent Cohort Study

TB Diagnosis and processes 6  All suspected participants were investigated through  Sputum smears cultures  Chest X-rays  Protocol defined case of TB : confirmed by two or more sputum smears (+) and/or one culture (+) * Uncertainty Zone : regarding QFT conversion, values falling in thes zone might not be “True conversion” [ 0.20 ~ 0.50 UL/ml]  “Doubtful conversion”

RESULT 7

RESULT 8

RESULT 9  Tuberculosis incidence rate ratio : ‘8.54’ for all cases

RESULT 10

RESULT 11  Uncertainty Zone [ 0.20 ~ 0.50 UL/ml ] ‘Doubtfull conversion’ : 116/ 534 (21.7%), 4/ 15 (26.7%)  QTF Reversion [ baseline IFN-g > 0.35 IU/ml, follow-up, <0.35 IU/ml ] : 241/ 2613

CONCLUSION 12  Recent QFT conversion was indicative of an approximately eight fold higher risk of progression to TB disease (compared with nonconverters) in a cohort of adolescents in a high–TB burden population  The predictive value of recent QFT conversion for the development of active TB disease is 2.6% within approximately 2 years after QFT conversion  Varying the definition of QFT conversion seems to have had minimal effect on the TB incidence rate in the QFT converter group

Comments 13  IPT(Isoniazid preventive therapy) for 100 adolescents, two or three subsequent TB cases would be averted  “Uncertainty Zone” showed 78% of QFT convertsions to be “true conversion”  A number of converters had less than 2 yrs follow up periods, and not all tests were available  The results of this study will strengthen the evidence base for IGRA guidelines,. However, a proper cost effectiveness analysis is needed to validate the use of these findings in low- and middle-income countries.